Vascular News and Research

RSS

Second-quarter fiscal 2010 results announced by Pharmacyclics

Pharmacyclics, Inc. today reported financial results for its second fiscal quarter ended December 31, 2009.

12 Feb 2010

Cancer drug could be effective for treating recurrent nose bleeds

Patients suffering from hereditary hemorrhagic telangiectasia (HHT), an inherited vascular condition characterized by profuse nosebleeds, may find hope in a cancer-fighting drug called bevacizumab, also known as Avastin.

12 Feb 2010

Therapeutic cell types obtained from iPS cells demonstrate abnormal expansion and early cellular aging

Advanced Cell Technology, Inc. or “ACT” reported that a range of therapeutic cell types obtained from induced pluripotent stem (iPS) cells exhibit abnormal expansion and early cellular aging. The research, which appears online (published-ahead-of- print) in the journal STEM CELLS by ACT and its collaborators at Stem International (SCRMI), Harvard Medical School, and the University of Illinois, compares a variety of replacement cell types derived from human iPS cells with their embryonic stem (ES) cell counterparts. The findings support the use of ACT’s single blastomere-derived human embryonic stem cell lines which do not display early aging.

12 Feb 2010

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.

11 Feb 2010

Boston Scientific combines Cardiovascular Group and Cardiac Rhythm Management Group

Boston Scientific Corporation today announced a series of management changes and restructuring initiatives designed to strengthen the Company and position it for long-term success.

11 Feb 2010

hESC and iPSC: Long-term stem cell evaluation and comparison study

For the first time, scientists have performed a detailed long-term evaluation and comparison of two different types of pluripotent stem cells: human embryonic stem cells (hESC) and induced pluripotency stem cells (iPSC). Both cell types are believed to share equal characteristics, abilities and potential to differentiate into nearly 220 different cell types. However, hESC are isolated from early human embryos and iPSC are derived from reprogrammed adult somatic cells which makes them less controversial.

11 Feb 2010

Bard FLAIR Endovascular Stent Graft more effective than balloon angioplasty for failing dialysis grafts

C. R. Bard, Inc. today announced the publication of trial results by The New England Journal of Medicine (NEJM) showing the Bard FLAIR® Endovascular Stent Graft maintains the patency of dialysis access grafts more effectively than balloon angioplasty alone. The FLAIR® Endovascular Stent Graft is the only implant approved by the U.S. Food and Drug Administration for use in the treatment of stenoses at the venous anastomosis of ePTFE or other synthetic arteriovenous access grafts.

11 Feb 2010

Therapeutic cell types obtained from iPS cells exhibit abnormal expansion and early cellular aging

Advanced Cell Technology, Inc. reported that a range of therapeutic cell types obtained from induced pluripotent stem (iPS) cells exhibit abnormal expansion and early cellular aging.

11 Feb 2010

Neurology researchers explore link between MS and chronic cerebrospinal venous insufficiency

More than 55 percent of multiple sclerosis patients participating in the initial phase of the first randomized clinical study to determine if persons with MS exhibit narrowing of the extracranial veins, causing restriction of normal outflow of blood from the brain, were found to have the abnormality.

11 Feb 2010

BioSphere Medical reports fourth-quarter and full-year 2009 results

BioSphere Medical, Inc. – the pioneer in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy – today reported financial results for the three and 12 months ended December 31, 2009.

10 Feb 2010

Candela receives SFDA approval to market its laser systems throughout China

Candela Corporation, a Syneron company, announced today that the SFDA (State Food and Drug Administration) of China has approved the Alex TriVantage® multi-wavelength, Q-switched laser system and the GentleMax® multiple wavelength workstation for sale throughout the People's Republic of China, including Hong Kong.

10 Feb 2010

HealthYes! brings mobile screening services to Colorado

HealthYes!®, a leading preventive medical screening company, is bringing its life-saving mobile screening services to Colorado. Leveraging the most medically advanced, state-of-the-art equipment and techniques in the industry, HealthYes! screens its clients for life-threatening medical conditions and diseases including: heart disease, stroke, abdominal aortic aneurysm, peripheral artery disease, diabetes and liver disease along with osteoporosis.

10 Feb 2010

Early life stress could be a risk factor for cardiovascular disease in adulthood

"We think early life stress increases sensitivity to a hormone known to increase your blood pressure and increases your cardiovascular risk in adult life," said Dr. Jennifer Pollock, biochemist in the Vascular Biology Center at the Medical College of Georgia and corresponding author on the study published online in Hypertension.

10 Feb 2010

FDA grants marketing clearance for Volcano's Eagle Eye Platinum digital IVUS catheter

Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Eagle Eye® Platinum digital IVUS catheter in the United States.

9 Feb 2010

Volcano acquires Xtract Thrombus Aspiration Catheter device from Lumen Biomedical

Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it has acquired the Xtract™ Thrombus Aspiration Catheter device line from Lumen Biomedical.

9 Feb 2010

Simple, inexpensive test for diagnosing cardiac-related chest pain

Researchers at the Methodist DeBakey Heart & Vascular Center have shown that a simple, inexpensive test can determine whether it is safe to send home a patient who comes to the emergency room with chest pain.

9 Feb 2010

Thrombogenics announces publication of positive microplasmin Phase II trial results

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that the positive microplasmin Phase II trial results, evaluating the product's efficacy and safety in patients who require vitrectomy, have been published in the prestigious American Academy of Ophthalmology's Journal, Ophthalmology, the leading journal for the vitreoretinal community.

9 Feb 2010

High BP may predict dementia in older adults with cognitive impairment

High blood pressure appears to predict the progression to dementia in older adults with impaired executive functions (ability to organize thoughts and make decisions) but not in those with memory dysfunction, according to a report in the February issue of Archives of Neurology, one of the JAMA/Archives journals.

9 Feb 2010

New nursing education modules now available from March of Dimes

For nurses seeking up-to-date and cost-effective continuing education on the care of mothers and babies, the March of Dimes is now offering three new publications (modules).

9 Feb 2010

Anthera Pharmaceuticals reaches agreement with the FDA on SPA for VISTA-16 clinical study

Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.

8 Feb 2010

Vascular News and Research

Second-quarter fiscal 2010 results announced by Pharmacyclics

Cancer drug could be effective for treating recurrent nose bleeds

Therapeutic cell types obtained from iPS cells demonstrate abnormal expansion and early cellular aging

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

Boston Scientific combines Cardiovascular Group and Cardiac Rhythm Management Group

hESC and iPSC: Long-term stem cell evaluation and comparison study

Bard FLAIR Endovascular Stent Graft more effective than balloon angioplasty for failing dialysis grafts

Therapeutic cell types obtained from iPS cells exhibit abnormal expansion and early cellular aging

Neurology researchers explore link between MS and chronic cerebrospinal venous insufficiency

BioSphere Medical reports fourth-quarter and full-year 2009 results

Candela receives SFDA approval to market its laser systems throughout China

HealthYes! brings mobile screening services to Colorado

Early life stress could be a risk factor for cardiovascular disease in adulthood

FDA grants marketing clearance for Volcano's Eagle Eye Platinum digital IVUS catheter

Volcano acquires Xtract Thrombus Aspiration Catheter device from Lumen Biomedical

Simple, inexpensive test for diagnosing cardiac-related chest pain

Thrombogenics announces publication of positive microplasmin Phase II trial results

High BP may predict dementia in older adults with cognitive impairment

New nursing education modules now available from March of Dimes

Anthera Pharmaceuticals reaches agreement with the FDA on SPA for VISTA-16 clinical study

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News